Given the serious consequences of constitutive STING deficiency or long-term suppression, caution should be exercised when contemplating STING modification as a therapeutic method in metabolic illnesses, including obesity. This evidence concerns the gene STING1 and obesity due to melanocortin 4 receptor deficiency.